Radiosensitizing effect of BRAF inhibitors in BRAF-mutated melanoma

被引：0
|
作者：
Hecht, M. [1 ]
Grabenbauer, M. [1 ]
Fietkau, R. [1 ]
Distel, L. V. [1 ]
Heinzerling, L. [2 ]
机构：
[1] Univ Hosp Erlangen, Radiat Oncol, Erlangen, Germany
[2] Univ Hosp Erlangen, Dermatol, Erlangen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0408
引用
收藏
页码：35 / 35
页数：1
相关论文
共 50 条
  • [31] Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells
    Schrama, D.
    Zhu, G.
    Goebeler, M.
    Houben, R.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 26 - 27
  • [32] Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells
    Zhu, Guannan
    Yi, Xiuli
    Haferkamp, Sebastian
    Hesbacher, Sonja
    Li, Chunying
    Goebeler, Matthias
    Gao, Tianwen
    Houben, Roland
    Schrama, David
    [J]. CANCER LETTERS, 2016, 376 (01) : 43 - 52
  • [33] Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells
    Schrama, D.
    Zhu, G.
    Goebeler, M.
    Houben, R.
    [J]. EXPERIMENTAL DERMATOLOGY, 2017, 26 (03) : E93 - E93
  • [34] Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
    Ryan J. Sullivan
    Omid Hamid
    Rene Gonzalez
    Jeffrey R. Infante
    Manish R. Patel
    F. Stephen Hodi
    Karl D. Lewis
    Hussein A. Tawbi
    Genevive Hernandez
    Matthew J. Wongchenko
    YiMeng Chang
    Louise Roberts
    Marcus Ballinger
    Yibing Yan
    Edward Cha
    Patrick Hwu
    [J]. Nature Medicine, 2019, 25 : 929 - 935
  • [35] BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer-A Case Series Study Target Therapy of BRAF-Mutated mCRC
    Yeh, Jen-Hao
    Tsai, Hsiang-Lin
    Chen, Yen-Cheng
    Li, Ching-Chun
    Huang, Ching-Wen
    Chang, Tsung-Kun
    Su, Wei-Chih
    Chen, Po-Jung
    Liu, Yu-Peng
    Wang, Jaw-Yuan
    [J]. MEDICINA-LITHUANIA, 2021, 57 (12):
  • [36] Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma
    Cebollero, Ana
    Puertolas, Teresa
    Pajares, Isabel
    Calera, Lourdes
    Anton, Antonio
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (04) : 458 - 462
  • [37] The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
    Vanni, Irene
    Tanda, Enrica Teresa
    Spagnolo, Francesco
    Andreotti, Virginia
    Bruno, William
    Ghiorzo, Paola
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [38] Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
    Sullivan, Ryan J.
    Hamid, Omid
    Gonzalez, Rene
    Infante, Jeffrey R.
    Patel, Manish R.
    Hodi, F. Stephen
    Lewis, Karl D.
    Tawbi, Hussein A.
    Hernandez, Genevive
    Wongchenko, Matthew J.
    Chang, YiMeng
    Roberts, Louise
    Ballinger, Marcus
    Yan, Yibing
    Cha, Edward
    Hwu, Patrick
    [J]. NATURE MEDICINE, 2019, 25 (06) : 929 - +
  • [39] A critical review of RAF inhibitors in BRAF-mutated glioma treatment
    Khoury, John-Victor El
    Wehbe, Sophie
    Attieh, Fouad
    Boutros, Marc
    Kesrouani, Carole
    Kourie, Hampig Raphael
    [J]. PHARMACOGENOMICS, 2024, 25 (07) : 343 - 355
  • [40] Immune checkpoint inhibitors in BRAF-mutated advanced colorectal cancer
    Kassab, Rebecca
    Khalil, Michel Abou
    Kassab, Joseph
    Kourie, Hampig Raphael
    [J]. FUTURE ONCOLOGY, 2023, 19 (36) : 2417 - 2424
12345